Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 5/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476598 | 1.00 | MAPT (0.44) | MAPTGRM5PDGFRBPDGFRACHRNB2 | |
| Hydrochloric Acid SCHEMBL1476494 | 0.99 | MAPT (0.43) | MAPTGRM5PDGFRBPDGFRACHRNB2 | |
| Hydrochloric Acid SCHEMBL1476495 | 0.99 | MAPT (0.43) | MAPTGRM5PDGFRBPDGFRACHRNB2 | |
| SCHEMBL1477491 | 0.84 | MAPT (0.47) | MAPTGRM5PDGFRBCHRNB2CHRNA4 | |
| SCHEMBL1477488 | 0.84 | MAPT (0.47) | MAPTGRM5PDGFRBCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL1477557 | 0.82 | MAPT (0.46) | MAPTGRM5PDGFRBCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL1477554 | 0.82 | MAPT (0.46) | MAPTGRM5PDGFRBCHRNB2CHRNA4 | |
| SCHEMBL1477293 | 0.77 | MAPT (0.56) | MAPTGRM5PDGFRBKDR | |
| SCHEMBL1477039 | 0.77 | MAPT (0.55) | MAPTGRM5EGLN1 | |
| Hydrochloric Acid SCHEMBL1477229 | 0.75 | MAPT (0.54) | MAPTGRM5EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | MAPT 3882/4885GRM5 48/4885PDGFRB 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.